The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- University of Erlangen-Nurnberg - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of University of Erlangen-Nurnberg human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University of Erlangen-Nurnberg with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the University of Erlangen-Nurnberg’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate University of Erlangen-Nurnberg’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of University of Erlangen-Nurnberg in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the University of Erlangen-Nurnberg’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with University of Erlangen-Nurnberg.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of University of Erlangen-Nurnberg and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
University of Erlangen-Nurnberg Snapshot 5
University of Erlangen-Nurnberg Overview 5
Key Information 5
Key Facts 5
University of Erlangen-Nurnberg - Research and Development Overview 6
Key Therapeutic Areas 6
University of Erlangen-Nurnberg - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
University of Erlangen-Nurnberg - Pipeline Products Glance 12
University of Erlangen-Nurnberg - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
University of Erlangen-Nurnberg Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
University of Erlangen-Nurnberg - Drug Profiles 15
5-Fluorouracil + Oxaliplatin + Calcium Folinate + Radiation 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
5-Fluorouracil + Oxaliplatin + Radiation therapy 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
5-FU + oxaliplatin 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Eplerenone 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Losartan 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Paclitaxel + Cisplatin + Radiation therapy 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Pioglitazone 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Preoperative Radiochemotherapy + 5-Fluorouracil for Advanced Rectal Cancer 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Spironolactone 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Telmisartan 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Etoricoxib 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Genotropin 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Recombinant CD40-Ligand Loaded Autologous Dendritic Cells Vaccine + Ontak 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Sorafenib + LBH589 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
University of Erlangen-Nurnberg - Pipeline Analysis 32
University of Erlangen-Nurnberg - Pipeline Products by Therapeutic Class 32
University of Erlangen-Nurnberg Pipeline Products By Target 35
University of Erlangen-Nurnberg - Pipeline Products by Route of Administration 37
University of Erlangen-Nurnberg - Pipeline Products by Molecule Type 38
University of Erlangen-Nurnberg - Locations And Subsidiaries 39
Head Office 39
Other Locations and Subsidiaries 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 41
Contact Us 41
Disclaimer 41List of Tables
University of Erlangen-Nurnberg - Pipeline by Therapy Area and Indication, 2010 8
University of Erlangen-Nurnberg - Pipeline by Stage of Development, 2010 9
University of Erlangen-Nurnberg - Monotherapy Products in Pipeline, 2010 10
University of Erlangen-Nurnberg - Combination Treatment Modalities in Pipeline, 2010 11
University of Erlangen-Nurnberg - Phase III, 2010 12
University of Erlangen-Nurnberg - Phase II, 2010 13
University of Erlangen-Nurnberg - Phase I, 2010 14
University of Erlangen-Nurnberg - Pipeline By Therapeutic Class, 2010 32
University of Erlangen-Nurnberg - Pipeline By Target, 2010 36
University of Erlangen-Nurnberg - Pipeline By Route of Administration, 2010 37
University of Erlangen-Nurnberg - Pipeline By Molecule Type, 2010 38
University of Erlangen-Nurnberg, Other Locations 39

List of Figures
University of Erlangen-Nurnberg - Pipeline by Therapy Area and Indication, 2010 7
University of Erlangen-Nurnberg - Pipeline by Stage of Development, 2010 9
University of Erlangen-Nurnberg - Monotherapy Products in Pipeline, 2010 10
University of Erlangen-Nurnberg - Combination Treatment Modalities in Pipeline, 2010 11
University of Erlangen-Nurnberg - Pipeline By Therapeutic Class, 2010 32
University of Erlangen-Nurnberg - Pipeline By Target, 2010 35
University of Erlangen-Nurnberg - Pipeline By Route of Administration, 2010 37
University of Erlangen-Nurnberg - Pipeline By Molecule Type, 2010 38

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...

Inhaled COPD Therapeutics Market

Inhaled COPD Therapeutics Market

  • $ 3 850
  • Industry report
  • June 2014
  • by Greystone Research Associates

COPD is not one but a family of conditions, each with its own etiology and treatment challenges. Chronic bronchitis is the inflammation and eventual scarring of the lining of the bronchial tubes. Oral ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.